# Taya Venture Capital

> Taya Venture Capital is a VC fund in Taiwan backing Biotechnology and Life Science. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Taiwan, China
- Total investments: 4
- Last investment: Jun 2025
- Lead investor: 25%
- Last updated: Aug 2026
- Website: https://www.tayaventure.com

Taya Venture Capital is a VC fund in Taiwan focused on Biotechnology and Life Science. Taya Venture Capital Co., Ltd. is a subsidiary of Daya Wire & Cable Group and has focused on discovering and investing in industries with growth potential. The company owns several professional investment funds, including Taya Ventures , Taya Innovation , Taya Genesis, and other NT dollar funds, as well as Taya Venture, a US dollar fund .

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $21M–$26M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Life Science | 2 | 50% |
| Biopharma | 1 | 25% |
| Health Care | 1 | 25% |
| Pharmaceutical | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 75% |
| Seed | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 75% |
| Taiwan | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Syncell | Syncell is a life science technology company building products for next-generation spatial biology. Its pioneering Microscoop™ technology enables microscopy-guided nanoscale protein "scooping", making unbiased subcellular spatial proteomics discovery feasible for the first time. This technology can be applied to a broad range ofbiological problems to help understand molecular mechanisms, identify novel disease biomarkers, and reveal novel druggable targets. | $25.7M | Series A | Jun 30, 2025 |  |
| Apeximmune Therapeutics | Apeximmune Therapeutics is pioneering a new generation of therapeutic antibodies and biologics that harness the power of the immune system to deliver curative treatments for cancer and autoimmune disease. | $21.3M | Series A | Mar 31, 2025 |  |
| Immunwork | Immunwork develops innovative drugs that combine targeting and effector functions to enhance efficacy and safety. The company focuses on creating ultralong-acting analogues, such as TE-8214, an octreotide derivative, and TE-8035, a modified human insulin. Immunwork's drug pipeline addresses immune system diseases and leverages a proprietarytechnology platform. The company is involved in clinical trials to validate its therapeutic solutions. | $23.7M | Series A | Mar 08, 2022 |  |
| Protuoso Biosciences | Protuoso Biosciences is a biotechnology company developing next-generation multifunctional biologics designed to address complex disease biology. | $9.5M | Seed |  |  |

4 of 4 investments shown.

## Co-investors
- [Center Ventures](https://shizune.co/investors/profile/center-ventures) — VC Fund, 1 deal together
- [Darwin Ventures](https://shizune.co/investors/profile/darwin-ventures) — VC Fund, 1 deal together
- [DCI Partners](https://shizune.co/investors/profile/dci-partners) — VC Fund, 1 deal together
- [First Capital Ventures](https://shizune.co/investors/profile/first-capital-ventures) — VC Fund, 1 deal together
- [Fubon Financial Holdings](https://shizune.co/investors/profile/fubon-technology-co) — VC Fund, 1 deal together
- [Hercules Bioventure Partners](https://shizune.co/investors/profile/hercules-bioventure-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [National Development Fund of Taiwan Government](https://shizune.co/investors/profile/national-development-fund-of-taiwan-government) — VC Fund
- [Darwin Venture Management](https://shizune.co/investors/profile/darwin-venture-management) — VC Fund
- [AVA Angels](https://shizune.co/investors/profile/ava-angels) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Taiwan](https://shizune.co/investors/biotechnology-investors-taiwan)
- [Health Care VC Funds in Taiwan](https://shizune.co/investors/health-care-vc-funds-taiwan)
- [Biotech Investors in Taiwan](https://shizune.co/investors/biotech-investors-taiwan)
- [Biotechnology VC Funds in Taiwan](https://shizune.co/investors/biotechnology-vc-funds-taiwan)
- [Biotech VC Funds in Taiwan](https://shizune.co/investors/biotech-vc-funds-taiwan)

## FAQ

### What does Taya Venture Capital invest in?

Taya Venture Capital invests primarily in Biotechnology, Life Science and Biopharma startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Taya Venture Capital's check size?

Taya Venture Capital typically joins rounds of $21M–$26M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Taya Venture Capital participates in.

### When did Taya Venture Capital last invest?

The most recent investment recorded for Taya Venture Capital closed in Jun 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co